EU/3/09/678

Table of contents

About

Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in January 2012 on request of the Sponsor.

On 8 October 2009, orphan designation (EU/3/09/678) was granted by the European Commission to Gregory Fryer Associates Ltd, United Kingdom, for (-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl) pyrrolidine-2, 5-dione for the treatment of soft tissue sarcoma.

For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.

Key facts

Active substance
(-)-trans-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1yl)-4-(1H-indol-3-yl) pyrrolidine-2, 5-dione
Disease / condition
Treatment of soft tissue sarcoma
Date of decision
08/10/2009
Outcome
Withdrawn
Orphan decision number
EU/3/09/678

Sponsor's contact details

Gregory Fryer Associates Ltd
30 St Thomas Place
Cambridgeshire Business Park
Ely, Cambridgeshire
CB7 4EX
United Kingdom
Tel. +44 (0)1353 645590
Fax +44 (0)1353 645599
E-mail: info@gf-associates.co.uk

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating